(RTTNews) - Eli Lilly and Company (LLY) reported detailed Phase 3 TRIUMPH-2 results showing that Retatrutide delivered substantial weight loss and blood sugar reductions in adults with obesity or overweight and type 2 diabetes. Participants receiving Retatrutide 12 mg lost an average of 49.6 pounds (20.8%) over 80 weeks, which A1C was reduced by up to 1.6%. More than half of treated participants no longer met the BMI criteria for obesity at the end of the study. Retatrutide is an investigational triple hormone receptor agonist designed to target GIP, GLP-1, and glucagon pathways. The drug is currently being evaluated for obesity, type 2 diabetes and related cardiometabolic conditions.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.